Bill > SB253

This bill, effective August 1, 2026, establishes new regulations concerning peptides by adding R.S. 37:23.5 to Louisiana law. It specifically prohibits professional or occupational licensing boards from preventing healthcare providers who can prescribe medication from giving patients peptides that are shipped from either a FDA-registered 503B outsourcing facility, which is a type of drug manufacturing facility that prepares sterile drugs for dispensing or administration to patients or other facilities, or a 503A compounding pharmacy, which is a pharmacy that compounds medications for individual patients based on a prescription. Both of these types of facilities must be in compliance with specific federal regulations (21 U.S.C. 353b and 21 U.S.C. 353a respectively) and relevant chapters of the United States Pharmacopeia - National Formulary, which are standards for drug quality. Furthermore, the bill prevents these licensing boards from prohibiting a Louisiana-licensed pharmacist working in a state-permitted pharmacy from compounding and dispensing peptides, provided that pharmacist also adheres to the same federal regulations and pharmacopeial standards.